Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
228 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Ischemia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Ischemia - Pipeline Review, H2 2014', provides an overview of the Ischemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ischemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ischemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ischemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Ischemia Overview 9 Therapeutics Development 10 Pipeline Products for Ischemia - Overview 10 Pipeline Products for Ischemia - Comparative Analysis 11 Ischemia - Therapeutics under Development by Companies 12 Ischemia - Therapeutics under Investigation by Universities/Institutes 16 Ischemia - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Ischemia - Products under Development by Companies 22 Ischemia - Products under Investigation by Universities/Institutes 26 Ischemia - Companies Involved in Therapeutics Development 27 Alize Pharma SAS 27 Amarantus Bioscience Holdings, Inc. 28 AnGes MG, Inc. 29 Apceth GmbH & Co. KG 30 Athersys, Inc. 31 Baxter International Inc. 32 Cellmid Limited 33 CoDa Therapeutics, Inc. 34 DNAVEC Corporation 35 GlaxoSmithKline plc 36 Hemostemix Ltd 37 Human Stem Cells Institute 38 IntelliCell BioSciences Inc. 39 Juventas Therapeutics, Inc. 40 Kasiak Research Pvt. Ltd. 41 Lixte Biotechnology Holdings, Inc. 42 Mast Therapeutics, Inc. 43 Miltenyi Biotec GmbH 44 Mirrx Therapeutics A/S 45 Multi Gene Vascular Systems Ltd 46 NeoStem, Inc. 47 Nuo Therapeutics, Inc. 48 Nyken BV 49 Opsona Therapeutics Ltd. 50 Pathfinder Cell Therapy, Inc. 51 PharmaIN Corporation 52 Pharmicell Co., Ltd. 53 Pluristem Therapeutics Inc. 54 Regado Biosciences, Inc. 55 ReNeuron Group plc 56 Sihuan Pharmaceutical Holdings Group Ltd. 57 Stempeutics Research Private Limited 58 Taxus Cardium Pharmaceuticals Group Inc. 59 TikoMed AB 60 Vericel Corporation 61 ViroMed Co., Ltd. 62 Ischemia - Therapeutics Assessment 63 Assessment by Monotherapy Products 63 Assessment by Target 64 Assessment by Mechanism of Action 66 Assessment by Route of Administration 68 Assessment by Molecule Type 70 Drug Profiles 72 AB-002 - Drug Profile 72 ACP-01 - Drug Profile 73 ALD-301 - Drug Profile 75 Alecmestencel-T - Drug Profile 77 alferminogene tadenovec - Drug Profile 78 AMR-001 - Drug Profile 79 AMRS-001 - Drug Profile 81 AntimiR-199a - Drug Profile 83 Aptamers for Cardiovascular Diseases - Drug Profile 84 ASCT-01 - Drug Profile 85 Autologous Vascular Cells Therapy - Drug Profile 86 AZP-531 - Drug Profile 87 beperminogene perplasmid - Drug Profile 88 bucillamine - Drug Profile 93 CD5-2 - Drug Profile 94 Cell Therapy for Critical Limb Ischemia - Drug Profile 95 Cell Therapy for Ischemia - Drug Profile 96 Cellgram for Severe Lower Limb Ischemia - Drug Profile 97 Cinepazide Mesylate - Drug Profile 98 CMK-103 - Drug Profile 99 DVC1-0101 - Drug Profile 101 EP-80317 - Drug Profile 102 Gene Therapy for Ischemic Heart Failure - Drug Profile 103 Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases - Drug Profile 104 GSK-1278863 - Drug Profile 105 ixmyelocel-T - Drug Profile 107 JVS-100 - Drug Profile 110 JVS-200 - Drug Profile 112 LB-100 - Drug Profile 113 LB-102 - Drug Profile 115 MicroRNA for Ischemia - Drug Profile 116 MultiGeneAngio - Drug Profile 117 MultiStem - Drug Profile 118 NRP-2945 - Drug Profile 121 NYK-1112 - Drug Profile 123 Oligonucleotide to Inhibit miRNA-26 for Ischemic Cardiovascular Disease - Drug Profile 124 Oligonucleotides for Immunology, Oncology, Infectious and Cardiovascular Disorders - Drug Profile 125 OPN-305 - Drug Profile 126 Pathfinder Cells - Drug Profile 128 Peptagon - Drug Profile 130 PGC Based hbEGF - Drug Profile 131 PMC-6 - Drug Profile 132 Protein for Myocardial Infarction and Critical Limb Ischemia - Drug Profile 134 PT-00114 - Drug Profile 135 Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug Profile 136 Recombinant Protein for Critical Limb Ischemia - Drug Profile 137 Recombinant Protein for Ischemia - Drug Profile 138 Recombinant Protein to Inhibit CXCL for Cardiovascular and Immunology - Drug Profile 139 Refacell-CLI - Drug Profile 140 ReN-009 - Drug Profile 141 Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 142 Small Molecules for Ischemia and Reperfusion Injury - Drug Profile 143 Small Molecules for Renal Failure and Renal Ischemia - Drug Profile 144 Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Drug Profile 145 Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile 146 Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile 147 Stem Cell Therapy for Cardiovascular Disease - Drug Profile 148 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 150 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 152 Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 153 Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 154 Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 155 Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Drug Profile 156 Stempeucel - Drug Profile 157 Stromal Cell Therapy for Critical Limb Ischemia - Drug Profile 160 TM-700 - Drug Profile 161 vepoloxamer - Drug Profile 162 VM-202 - Drug Profile 163 Ischemia - Recent Pipeline Updates 165 Ischemia - Dormant Projects 209 Ischemia - Discontinued Products 215 Ischemia - Product Development Milestones 216 Featured News & Press Releases 216 Appendix 222 Methodology 222 Coverage 222 Secondary Research 222 Primary Research 222 Expert Panel Validation 222 Contact Us 223 Disclaimer 223
List of Tables Number of Products under Development for Ischemia, H2 2014 15 Number of Products under Development for Ischemia - Comparative Analysis, H2 2014 16 Number of Products under Development by Companies, H2 2014 18 Number of Products under Development by Companies, H2 2014 (Contd..1) 19 Number of Products under Development by Companies, H2 2014 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2014 22 Comparative Analysis by Late Stage Development, H2 2014 23 Comparative Analysis by Clinical Stage Development, H2 2014 24 Comparative Analysis by Early Stage Development, H2 2014 25 Comparative Analysis by Unknown Stage Development, H2 2014 26 Products under Development by Companies, H2 2014 27 Products under Development by Companies, H2 2014 (Contd..1) 28 Products under Development by Companies, H2 2014 (Contd..2) 29 Products under Development by Companies, H2 2014 (Contd..3) 30 Products under Investigation by Universities/Institutes, H2 2014 31 Ischemia - Pipeline by Alize Pharma SAS, H2 2014 32 Ischemia - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2014 33 Ischemia - Pipeline by AnGes MG, Inc., H2 2014 34 Ischemia - Pipeline by Apceth GmbH & Co. KG, H2 2014 35 Ischemia - Pipeline by Athersys, Inc., H2 2014 36 Ischemia - Pipeline by Baxter International Inc., H2 2014 37 Ischemia - Pipeline by Cellmid Limited, H2 2014 38 Ischemia - Pipeline by CoDa Therapeutics, Inc., H2 2014 39 Ischemia - Pipeline by DNAVEC Corporation, H2 2014 40 Ischemia - Pipeline by GlaxoSmithKline plc, H2 2014 41 Ischemia - Pipeline by Hemostemix Ltd, H2 2014 42 Ischemia - Pipeline by Human Stem Cells Institute, H2 2014 43 Ischemia - Pipeline by IntelliCell BioSciences Inc., H2 2014 44 Ischemia - Pipeline by Juventas Therapeutics, Inc., H2 2014 45 Ischemia - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 46 Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2014 47 Ischemia - Pipeline by Mast Therapeutics, Inc., H2 2014 48 Ischemia - Pipeline by Miltenyi Biotec GmbH, H2 2014 49 Ischemia - Pipeline by Mirrx Therapeutics A/S, H2 2014 50 Ischemia - Pipeline by Multi Gene Vascular Systems Ltd, H2 2014 51 Ischemia - Pipeline by NeoStem, Inc., H2 2014 52 Ischemia - Pipeline by Nuo Therapeutics, Inc., H2 2014 53 Ischemia - Pipeline by Nyken BV, H2 2014 54 Ischemia - Pipeline by Opsona Therapeutics Ltd., H2 2014 55 Ischemia - Pipeline by Pathfinder Cell Therapy, Inc., H2 2014 56 Ischemia - Pipeline by PharmaIN Corporation, H2 2014 57 Ischemia - Pipeline by Pharmicell Co., Ltd., H2 2014 58 Ischemia - Pipeline by Pluristem Therapeutics Inc., H2 2014 59 Ischemia - Pipeline by Regado Biosciences, Inc., H2 2014 60 Ischemia - Pipeline by ReNeuron Group plc, H2 2014 61 Ischemia - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2014 62 Ischemia - Pipeline by Stempeutics Research Private Limited, H2 2014 63 Ischemia - Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H2 2014 64 Ischemia - Pipeline by TikoMed AB, H2 2014 65 Ischemia - Pipeline by Vericel Corporation, H2 2014 66 Ischemia - Pipeline by ViroMed Co., Ltd., H2 2014 67 Assessment by Monotherapy Products, H2 2014 68 Number of Products by Stage and Target, H2 2014 70 Number of Products by Stage and Mechanism of Action, H2 2014 72 Number of Products by Stage and Route of Administration, H2 2014 74 Number of Products by Stage and Molecule Type, H2 2014 76 Ischemia Therapeutics - Recent Pipeline Updates, H2 2014 170 Ischemia - Dormant Projects, H2 2014 214 Ischemia - Dormant Projects (Contd..1), H2 2014 215 Ischemia - Dormant Projects (Contd..2), H2 2014 216 Ischemia - Dormant Projects (Contd..3), H2 2014 217 Ischemia - Dormant Projects (Contd..4), H2 2014 218 Ischemia - Dormant Projects (Contd..5), H2 2014 219 Ischemia - Discontinued Products, H2 2014 220
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
